Reported about 3 hours ago
Novo Nordisk has disbanded its U.S. obesity and diabetes education sales team, marking a significant cost-cutting move as part of a broader restructuring plan that will see 9,000 global job cuts. The decision reflects the company's efforts to regain competitiveness against rival Eli Lilly, after experiencing a significant drop in market share and capitalization. Affected employees were informed they would be terminated but would receive pay until year-end.
Source: YAHOO